Gene therapy · Gene replacement · developed by Krystal Biotech
KB301 is a non-integrating herpes simplex virus type 1 vector that delivers a gene expressing human type III collagen. It is studied in skin roughness, wrinkles, fine lines and skin thickness.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04540900 | Phase 1 | Skin Roughness | Active not recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fine LinesSkin RoughnessSkin ThicknessWrinkle
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →